Clinical Biomarkers Market to be dominated by Growing Occurrences of Cancer through 2027
Growing occurrences of infectious diseases and various types of
cancers to drive the clinical biomarkers market in the forecast period, 2023-2027.
According to TechSci Research report, “Clinical
Biomarkers Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2017-2027”, the global clinical biomarkers market is
anticipated to grow at a significant rate in the forecast period, 2023-2027. The
growing prevalence of infectious diseases and various type of cancer, rise in research
and development activities, and adoption of advanced technology are the primary
factors driving the demand for the global clinical biomarkers market. The increasing
demand for personalized treatment, surge in the number of patients, rising
healthcare burden, growing geriatric base, and rising funding for research and
technological development are expected to influence the market demand. Also, the
surge in number of strategies such as partnerships, collaborations, and product
launches undertaken by the market players are also a key factor for supporting
the growth of the clinical biomarkers market, globally.
However, the higher cost of product/service
hindering the development in low-income countries, complex regulatory
frameworks delaying the approval of new clinical biomarkers tests and lack of
skilled professionals may hamper the growth of the global clinical biomarkers market.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Clinical Biomarkers Market"
The global clinical
biomarkers market is segmented into product, services, technology, clinical
area, application, end user, and company.
Based on product, the market
is divided into efficacy biomarkers, safety biomarkers, and validation
biomarkers. The safety biomarkers segment
is expected to hold the largest market share. This is attributed to the increased
public awareness of the significance of regular health screenings and rise in
the population who are at a higher risk of contracting diseases such as cancer,
cardiovascular disease, and others.
Based on services, the
market is divided into genomic biomarker service, tissue biomarker service,
cell service, and proteomics service. The genomic biomarker service segment is
anticipated to grow during the forecast period. This is attributed to the growing
number of patients and increasing incidences of cancer.
Based on technology, the
market is divided into next generation sequencing, polymerase chain reaction,
immunohistochemistry, enzyme-linked immunosorbent assay, and others. The next
generation sequencing segment is anticipated to grow during the forecast period.
This is attributed to the growing cancer genomics research.
Based on clinical area, the
market is divided into cancer biomarker, cardiac biomarker, neurological
biomarker, infectious disease biomarker, and others. The cancer biomarker
segment is anticipated to grow during the forecast period. This is attributed
to the growing cancer cases across the globe.
Based on application, the
market is divided into translational research and clinical diagnostics. The translational
research segment is anticipated to grow during the forecast period.
Based on end user, the
market is divided into biotechnology & pharmaceutical companies, diagnostic
centers, academic & research institutions, and others. The academic &
research institutions segment is anticipated to grow during the forecast
period. This is attributed to the growing research in various fields such as
genomics, proteomics, and biomedicine, and also due to rising occurrences of
diseases.
Major companies operating
in global clinical biomarkers market are:
- Agilent Technologies, Inc.
- Illumina, Inc.
- F. Hoffmann-La Roche AG
- QIAGEN NV
- PerkinElmer, Inc
- Thermo Fischer Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- NeoGenomics Laboratories, Inc.
- Charles River Laboratories International,
Inc.
- Quest Diagnostics, Inc.
- Abbott Laboratories, Inc.
- bioMérieux S.A.
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the market in 2021 and is expected to maintain
its dominance in the coming years due to increasing prevalence of infectious diseases,
and various type of cancer, and rise in the R&D activities. The extensive
development in technology, high adoption rate of cancer genomics research, well-established
research infrastructure, strong presence of prominent players, and growing government
initiatives in the healthcare sector in the region are another key factor. Also,
increasing adoption of expansion strategies and rise in medical tourism in the
region are expected to propel the global clinical biomarkers market growth till
2027” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Clinical Biomarkers Market
- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented
By Product (Efficacy Biomarkers, Safety
Biomarkers, Validation Biomarkers), By Services (Genomic Biomarker Service,
Tissue Biomarker Service, Cell Service, Proteomics Service), By Technology
(Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry,
Enzyme-Linked Immunosorbent Assay, Others), By Clinical Area (Cancer Biomarker,
Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Others),
By Application (Translational Research v/s Clinical Diagnostics), By End User
(Biotechnology & Pharmaceutical Companies, Diagnostic Centers, Academic
& Research Institutions, Others), By company and By Region”, has evaluated the future growth potential of global clinical
biomarkers market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in global clinical biomarkers market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com